MARKET OVERVIEW
The India intravenous solution market was valued at USD 1.90 Billion in 2024 and is projected to reach USD 2.96 Billion by 2033, growing at a CAGR of 4.81% during the forecast period 2025-2033. This growth is driven by increasing medical procedures, chronic illness prevalence, improving healthcare access, and rising demand for total parenteral nutrition (TPN) and non-PVC bags. The market shows strong regional dominance in Central India with significant opportunities across urban and rural healthcare segments. The report presents a thorough review featuring the India Intravenous Solution Market growth, share, trends, and research of the industry.
STUDY ASSUMPTION YEARS
- Base Year: 2024
- Historical Year/Period: 2019-2024
- Forecast Year/Period: 2025-2033
INDIA INTRAVENOUS SOLUTION MARKET KEY TAKEAWAYS
- Current Market Size: USD 1.90 Billion in 2024
- CAGR: 4.81% from 2025 to 2033
- Forecast Period: 2025-2033
- Central India dominates the market holding 35.00% market share.
- Market growth is driven by rising medical procedures, chronic illness cases, and improved healthcare access.
- Increasing demand for total parenteral nutrition (TPN) and non-PVC bags significantly boost market share.
- Expansion of ICU capacities and medical tourism enhances intravenous solution consumption across India.
Sample Request Link: https://www.imarcgroup.com/india-intravenous-solution-market/requestsample
MARKET TRENDS
The use of total parenteral nutrition (TPN) is rising significantly within critical care and neonatal settings in India due to its efficacy for patients unable to be fed orally or enterally. Hospitals are increasing ICU capacities and adopting nutrition protocols, particularly in oncology departments where patients require specialized nutritional support. This trend enhances TPN demand, which held around 56.7% market share in 2024.
Hospitals across India prefer premixed and ready-to-use IV solutions that improve safety and operational efficiency. These prefilled formulations reduce contamination risk and dosage errors crucial in emergency care scenarios. The shift towards standardized care and advanced multi-specialty hospitals supports this expanding segment.
There is a notable trend toward adoption of non-PVC IV bags due to concerns over DEHP plasticizers in traditional PVC bags potentially harming patients. Focus on patient safety, especially neonates and cancer patients, drives this shift. Manufacturers are introducing eco-friendly DEHP-free alternatives supported by tightening regulatory and hospital procurement standards.
MARKET GROWTH FACTORS
Rising cases of dehydration, chronic illnesses, and surgical procedures in Indian hospitals fuel IV solution demand. Growth is further supported by the expanding elderly population projected to rise from 153 Million to 347 Million by 2050, increasing the incidence of gastrointestinal and chronic disorders requiring fluid replacement therapies.
Government emphasis on rural healthcare infrastructure improvement and increased medical tourism have pushed hospitals and clinics to maintain consistent IV fluid supply, particularly in high-patient-influx states. Private investments in specialty and multi-specialty hospitals alongside expanding health insurance contribute to broader intravenous therapy access.
Pharmaceutical industry growth also propels market expansion, with increased approvals of injectable formulations and launches of novel IV drugs such as Glenmark Pharmaceuticals' AKYNZEO I.V., improving treatment compliance. Partnerships and investments, for example, Sanjivani Paranteral's Rs 50 crore investment in a Pune manufacturing facility, further enhance healthcare delivery and pharmaceutical standards.
MARKET SEGMENTATION
Analysis by Type
- Partial Parenteral Nutrition: Not provided in source.
- Total Parenteral Nutrition: Holds around 56.7% of the market in 2024. It is crucial for malnourished patients in ICUs, oncology wards, and neonatal care, delivering essential nutrients intravenously when oral or enteral feeding is not feasible.
Analysis by Nutrients
- Carbohydrates: Not provided in source.
- Salts and Electrolytes: Lead the market with around 42.7% share in 2024, commonly used to treat dehydration, electrolyte imbalances, and surgical recovery.
- Minerals: Not provided in source.
- Vitamins: Not provided in source.
- Amino Acids: Not provided in source.
Regional Analysis
- North India: Not provided in source.
- West and Central India: Accounted for the largest market share of over 35.0% in 2024; features the highest concentration of healthcare facilities and pharmaceutical hubs.
- South India: Not provided in source.
- East India: Not provided in source.
REGIONAL INSIGHTS
West and Central India dominate the market with over 35.0% market share in 2024, attributed to advanced hospital infrastructure, numerous healthcare facilities, and manufacturing units in states like Maharashtra, Gujarat, and Madhya Pradesh. This region benefits from strong distribution networks and a high volume of surgical and chronic disease cases, driving consistent market growth.
RECENT DEVELOPMENTS & NEWS
In February 2025, Aakash Healthcare launched North India's first dedicated Vein Clinic in partnership with Medtronic. This facility offers advanced, minimally invasive treatments for varicose veins, aiming to address chronic pain and related complications. This collaboration strengthens vascular treatment options and promotes better patient outcomes through enhanced awareness and comprehensive care.
KEY PLAYERS
- Piramal Enterprises Limited
- Troikaa Pharmaceuticals Ltd
- Baxter India (Baxter International Inc.)
- Fresenius Kabi India Pvt. Ltd. (Fresenius SE & Co. KGaA)
- Amanta Healthcare Ltd.
- Otsuka Pharmaceutical India Pvt. Ltd.
- Abaris Healthcare Pvt. Ltd.
If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.
Ask Analyst For Customized Market Report: https://www.imarcgroup.com/request?type=report&id=2944&flag=E
ABOUT US
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provide a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.
CONTACT US
IMARC Group,
134 N 4th St. Brooklyn, NY 11249, USA,
Email: [email protected],
Tel No: (D) +91 120 433 0800,
United States: +1-201971-6302
